To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
TMEM115 Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse TMEM115 for immunoprecipitation of endogenous golgi.This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Mid 2026
TMEM192 Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse TMEM192 for immunoprecipitation of endogenous lysosomes.This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Mid 2026
VPS13C Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse VPS13C. Developed for use in immunoblotting and immunohistochemistry applications. This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Late 2025
VPS13C Knockout HeLa Cell Line
Immortalized Cell
HeLa cell with homozygous knockout of VPS13C. This cell line development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative.
ATP13A2 Antibody
Antibody
Rabbit monoclonal antibody directed against human ATP13A2 for immunoblotting, immunostaining, and immunoprecipitation applications. This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Early 2026
ATP10B Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse ATP10B for immunoblotting and immunostaining applications. This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Late 2025
ATP10B Knockout LS513 Cell Line
Immortalized Cell
LS513 cell line with homozygous knockout of APT10B. This cell line development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative.
ATP13A2 Antibody
Antibody
Rabbit monoclonal antibody directed against mouse ATP13A2 for immunoblotting, immunostaining, and immunoprecipitation applications. This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Early 2026
MCI-PARK Mouse*
Mouse Model
Homozygous knockout mice targeting Ndufs2 (NADH:ubquinone oxidoreductase core subunit S2) specifically in dopaminergic neurons. Mice with floxed Ndufs2 allele were crossed with mice expressing Cre recombinase under the control of Slc6ac (dopamine transporter; DAT) promoter. Model was generated by D. James Surmeier at Northwestern University and deposited through the MJFF Sponsored Tools Program as part of the Aligning Science Across Parkinson’s (ASAP) Initiative. RRID:IMSR_JAX:036313
iMCI-PARK Mouse*
Mouse Model
Inducible MCI-PARK (iMCI-PARK) mice, based on the ESR-NDUFS2 strain described by Fernández-Agüera, 2015, were generated by crossing mice carrying a floxed allele of mouse Ndufs2 with mice that broadly express tamoxifen-inducible cre recombinase (Tg(CAG-cre/Esr1*)5Amc that result in a conditional, body-wide knock-out of Ndufs2 following tamoxifen induction. Model was originally designed by deleting Ndufs2 only from dopaminergic neurons by D. James Surmeier at Northwestern University and made available through the MJFF Sponsored Tools Program as part of the Aligning Science Across Parkinson’s (ASAP) Initiative. RRID:IMSR_JAX:038571
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic